Showing results (1811-1820 of 2,064) with videos related to

Sort By:
Pageof 207
Brachytherapy|September 26, 2017
Time-resolved in vivo dosimetry for source tracking in brachytherapyJacob Graversen Johansen, Susanne Rylander, Simon Buus, et al.
Brachytherapy|September 30, 2017
Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinomaScott E Jordan, Ida Micaily, Enrique Hernandez, et al.
Brachytherapy|July 30, 2017
High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemesAlexander T Falk, Sylvain Demontoy, Emmanuel Chamorey, et al.
Brachytherapy|July 4, 2016
Tumor dose-volume response in image-guided adaptive brachytherapy for cervical cancer: A meta-regression analysisRenaud Mazeron, Pauline Castelnau-Marchand, Alexandre Escande, et al.
Brachytherapy|December 23, 2017
Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II studyPierre Blanchard, Thomas J Pugh, David A Swanson, et al.
Brachytherapy|February 28, 2018
Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancerMarc Gaudet, Mathieu Pharand-Charbonneau, Marie-Pierre Desrosiers, et al.
Brachytherapy|March 3, 2018
Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancerAmandeep S Taggar, Kenneth L Pitter, Gil'ad N Cohen, et al.
Brachytherapy|January 7, 2018
Efficacy and the toxicity of the interstitial high-dose-rate brachytherapy in the management of recurrent keloids: 5-year outcomesPing Jiang, Matthias Geenen, Frank-André Siebert, et al.
Brachytherapy|January 8, 2018
A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failureDaniel Taussky, Stéphane Bedwani, Nissan Meissner, et al.
Brachytherapy|February 6, 2018
A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recoveryM A Korzeniowski, J M Crook, D Bowes, et al.
Pageof 207